(NewsDirect)
Oxford Cannabinoid Technologies HoldingsPLC (LSE:OCTP, OTC:OCTHF) CEO Clarissa Sowemimo Coker and CMO Dr TimCorn speak to Thomas Warner from Proactive after the pharmaceuticalgroup announced the appoint of Corn to its board of directors.
The move follows his appointment as ChiefMedical Officer in June 2023. Sowemimo-Coker highlights the importanceof having a clinician on the board of a biopharmaceutical company. Theappointment follows the successful announcement of Phase I singleascending dose results in October, reflecting OCT's commitment toaddressing unmet medical needs with novel therapeuticapproaches.
Dr. Corn cites thecombination of addressing unmet medical needs and the use of a novelcannabinoid approach as key factors that have attracted him to thebusiness. He outlines his dual focus in the role, continuing as CMO toensure efficient clinical programs aligned with regulatoryrequirements and bringing a physician's perspective to the board.He suggests that his expertise in clinical development and board workpositions him well to balance patient interests and financialconsiderations.
Discussing thecompany's cash runway, Sowemimo-Coker says the company is fundedinto April 2024. She assures stakeholders that the board is activelyexploring various funding options, and updates will be provided asprogress unfolds. While the details remain confidential, she hints atpotential updates before the end of the year.
The interview showcased OCT'scommitment to advancing cannabinoid-based therapies, building a strongleadership team, and maintaining transparency in financial matters.Stakeholders are eagerly anticipating further developments as OCTcontinues its journey towards clinical and financial success.
Contact Details
Proactive UK Ltd
+44 207989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.